マルチモーダルイメージング市場：技術別（PET-CT、SPECT-CT、PET-MR、OCT/FMT）、用途別（腫瘍学、心臓病学、脳科学、眼科学）、エンドユーザー別（病院、診断センター、学術機関、研究）、地域別 - 2028年までの世界予測

Multimodal Imaging Market by Technology (PET-CT, SPECT-CT, PET-MR, OCT/FMT), Application (Oncology, Cardiology, Brain, Ophthalmology), End User (Hospitals, Diagnostic Centers, Academia, Research) & Region - Global Forecast to 2028

世界のマルチモーダル市場は、2023年の42億米ドルから2028年には55億米ドルに達すると予測され、2023年から2028年までの年平均成長率は5.7%である。対象疾患の罹患率/有病率の高さ、画像診断センター/処置数の増... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2023年9月1日	US$4,950 シングルユーザライセンスライセンス・価格情報注文方法はこちら	213	143	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

世界のマルチモーダル市場は、2023年の42億米ドルから2028年には55億米ドルに達すると予測され、2023年から2028年までの年平均成長率は5.7%である。対象疾患の罹患率/有病率の高さ、画像診断センター/処置数の増加、疾患の早期診断の利点に関する意識の高まり、技術的に先進的な画像診断システム、機能、モダリティの急速な採用などの要因が、この市場の成長拡大に寄与している。

"PET-CTの技術セグメントlが2022年の市場で最大シェアを占める"
技術に基づき、マルチモーダル市場はPET-CT、PET/MR、SPECT-CT、OCT/FMT、その他のマルチモーダルイメージングに区分される。PET-CTセグメントが市場の主要シェアを占めている。PETとCTスキャンを1回で実施することにより、放射線被ばくとスキャン時間が短縮され、その臨床的汎用性は腫瘍学、心臓病学、神経学、感染症学に及ぶ。初期費用はかかるものの、PET-CTの費用対効果は、診断の改善、追加検査の必要性の減少、研究の進歩から現れ、患者の転帰と医学研究に大きな利益をもたらす価値あるツールとなっており、この製品セグメントの成長を牽引している。

"腫瘍学セグメントは予測期間中に最も高いCAGRを記録すると予測されている"
アプリケーションに基づき、マルチモーダル市場は脳・神経学、心臓病学、腫瘍学、眼科学、研究およびその他のアプリケーションに区分される。2022年に最大の市場シェアを占めたのは腫瘍学分野であった。このセグメントの大きなシェアは、システムの多用途性、画質、高度な機能、使いやすさに加え、病院や医療機関における急性期医療や救急医療での利用が増加していることに起因している。

"エンドユーザー別の画像診断センターセグメントは予測期間中に大きなCAGRを記録すると予測されている"
エンドユーザー別に見ると、マルチモーダル市場は病院、画像診断センター、学術・研究機関に区分される。2022年のマルチモーダル市場で最大のシェアを占めたのは、画像診断センター部門であった。PET-CT、MRI-PET、SPECT-CTなど複数の画像モダリティを統合することで、画像診断センターはより正確で信頼性の高い診断を提供でき、より良い治療計画と患者の転帰改善につながる。さらに、マルチモーダルイメージングの汎用性により、これらのセンターは幅広い診療科目に対応することができ、多様な医療ニーズを持つ患者に効果的にサービスを提供することができる。

"北米地域の市場は予測期間中に最も高い成長が見込まれる"
北米地域のマルチモーダル市場は、予測期間中にCAGRを記録することが期待されており、その主な理由は、同地域における高い医療費、対象疾患の有病率の上昇、研究活動の増加、美容整形手術の増加、イメージングシステムの技術進歩などである。

本レポートで参照した主要参入企業の内訳は以下の通りである：
- 企業タイプ別Tier1-48％、Tier2-36％、Tier3-16
- 役職別ディレクターレベル-14%、Cレベル-10%、その他-76
- 地域別北米-40%、欧州-32%、アジア太平洋地域-20%、中南米-5%、中東・アフリカ-3

マルチモーダル市場の主要企業は、GEヘルスケア（米国）、Koninklijke Philips N.V.（オランダ）、キヤノンメディカルシステムズ（日本）、シーメンスAG（ドイツ）、東軟（中国）、トプコン（日本）、ブルカー（米国）などである。

調査範囲

本レポートでは、マルチモーダル市場を技術、ディスプレイ、携帯性、コンポーネント、アプリケーション、エンドユーザー、地域別に調査しています。また、市場成長に影響を与える要因を網羅し、市場における様々な機会と課題を分析し、市場リーダーのための競争環境の詳細を提供します。さらに、本レポートでは、ミクロ市場の成長動向を分析し、主要5地域（およびこれらの地域の各国）に関する市場セグメントの収益を予測しています。

レポート購入の理由
本レポートは、マルチモーダル市場全体とサブセグメントの収益数値の最も近い近似値に関する情報を提供することで、市場リーダー/新規参入者に役立ちます。本レポートは、利害関係者が競争状況を理解し、より多くの洞察を得ることで、事業の位置づけを高め、適切な市場参入戦略を計画するのに役立ちます。また、本レポートは、関係者が市場の脈動を理解し、主要な市場促進要因、阻害要因、課題、機会に関する情報を提供するのに役立ちます。

本レポートは、以下のポイントに関する洞察を提供します：
- マルチモーダル市場の成長に影響を与える主な促進要因（対象患者数の増加、マルチモーダル画像診断装置の採用拡大、技術進歩、官民組織による投資・資金・助成金の増加）、阻害要因（資本コストと運用コストの高さ、不利な規制ガイドライン）、機会（新興国全体の医療インフラの改善、乳房画像診断におけるPETの利用、有望な製品パイプライン）、課題（代替画像診断技術の利用可能性）の分析
- 製品開発/イノベーション：マルチモーダル市場における今後の技術、研究開発活動、新製品・サービスの発売に関する詳細な洞察
- 市場開発：有利な市場に関する包括的な情報-当レポートは様々な地域のマルチモーダル市場を分析しています。
- 市場の多様化：マルチモーダル市場における新製品、未開拓地域、最近の開発、投資に関する詳細な情報
- 競合評価：GE Healthcare社（米国）、Koninklijke Philips N.V.社（オランダ）、キヤノンメディカルシステムズ株式会社（日本）、シーメンス株式会社（ドイツ）、Neusoft社（中国）、株式会社トプコン（日本）、Bruker社（米国）などの主要企業の市場シェア、成長戦略、サービス内容を詳細に評価。

ページTOPに戻る

1 INTRODUCTION 24
1.1 STUDY OBJECTIVES 24
1.2 MARKET DEFINITION 24
1.2.1 INCLUSIONS & EXCLUSIONS 25
1.3 STUDY SCOPE 25
1.3.1 MARKETS COVERED 25
1.3.2 GEOGRAPHICAL SEGMENTATION 26
1.4 YEARS CONSIDERED 26
1.5 CURRENCY 27
1.6 RESEARCH LIMITATIONS 27
1.7 STAKEHOLDERS 27
1.8 SUMMARY OF CHANGES 28
2 RESEARCH METHODOLOGY 29
2.1 RESEARCH DATA 29
FIGURE 1 MULTIMODAL IMAGING MARKET: RESEARCH DESIGN 29
2.1.1 SECONDARY RESEARCH 30
2.1.2 PRIMARY RESEARCH 31
2.1.2.1 Primary sources 32
2.1.2.2 Key industry insights 33
2.1.2.3 Breakdown of primaries 34
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 34
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 34
2.2 MARKET SIZE ESTIMATION 35
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 36
2.2.1 BOTTOM-UP APPROACH 36
2.2.1.1 Approach 1: Company revenue estimation approach 36
FIGURE 5 MARKET SIZE ESTIMATION FOR MULTIMODAL IMAGING: APPROACH 1 (COMPANY REVENUE ESTIMATION) 37
FIGURE 6 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF SIEMENS HEALTHINEERS 38
2.2.1.2 Approach 2: Customer-based market estimation 38
2.2.1.3 Multimodal imaging market: Top-down approach 39
2.2.1.4 Approach 3: CAGR projections 39
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 39
2.3 DATA TRIANGULATION 40
FIGURE 8 DATA TRIANGULATION METHODOLOGY 40
2.4 MARKET SHARE ASSESSMENT 41
2.5 STUDY ASSUMPTIONS 41
2.6 GROWTH RATE ASSUMPTIONS 42
2.7 RISK ASSESSMENT 42
2.7.1 MULTIMODAL IMAGING MARKET: RISK ASSESSMENT 42
2.8 RECESSION IMPACT 42
3 EXECUTIVE SUMMARY 44
FIGURE 9 MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION) 44
FIGURE 10 MULTIMODAL IMAGING MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 45
FIGURE 11 MULTIMODAL IMAGING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 46
FIGURE 12 GEOGRAPHICAL SNAPSHOT OF MULTIMODAL IMAGING MARKET 47
4 PREMIUM INSIGHTS 48
4.1 MULTIMODAL IMAGING MARKET OVERVIEW 48
FIGURE 13 TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSTIC IMAGING MODALITIES TO DRIVE MARKET 48
4.2 NORTH AMERICA: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION) 49
FIGURE 14 PET/CT MULTIMODAL IMAGING SYSTEMS TO DOMINATE NORTH AMERICAN MARKET IN 2023 49
4.3 ASIA PACIFIC: MULTIMODAL IMAGING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 50
FIGURE 15 HOSPITALS TO DOMINATE ASIA PACIFIC MARKET IN 2023 50
4.4 EUROPE: MULTIMODAL IMAGING MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 51
FIGURE 16 ONCOLOGY SEGMENT TO DOMINATE EUROPEAN MARKET DURING FORECAST PERIOD 51
4.5 MULTIMODAL IMAGING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 52
FIGURE 17 CHINA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 52
5 MARKET OVERVIEW 53
5.1 INTRODUCTION 53
5.2 MARKET DYNAMICS 54
FIGURE 18 MULTIMODAL IMAGING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 54
5.2.1 DRIVERS 54
5.2.1.1 Growing applications of multimodal imaging systems 54
5.2.1.2 Technological advancements in diagnostic imaging modalities 55
TABLE 1 TECHNOLOGICAL ADVANCEMENTS IN MULTIMODAL IMAGING SYSTEMS 55
5.2.1.3 Availability of funding for research 57
5.2.1.4 Increasing establishment of hospitals and diagnostic imaging centers 58
5.2.2 RESTRAINTS 58
5.2.2.1 Unfavorable healthcare reforms 58
5.2.2.2 High capital and operational cost 59
5.2.2.3 Lack of adequate healthcare infrastructure 59
5.2.3 OPPORTUNITIES 59
5.2.3.1 Availability of reimbursement and insurance coverage for scans 59
TABLE 2 CODES FOR SPECT/CT FUSION IMAGING (AS OF 2021) 60
TABLE 3 NATIONAL PET, PET/CT COVERAGE FOR ONCOLOGY (AS OF 2021) 60
5.2.3.2 Increasing R&D into radiotracers 61
5.2.4 CHALLENGES 61
5.2.4.1 Growing end-user preference for refurbished equipment 61
5.2.4.2 Dearth of trained professionals 62
5.3 PORTER’S FIVE FORCES ANALYSIS 62
TABLE 4 MULTIMODAL IMAGING MARKET: PORTER’S FIVE FORCES ANALYSIS 62
5.3.1 THREAT OF NEW ENTRANTS 62
5.3.2 THREAT OF SUBSTITUTES 63
5.3.3 BARGAINING POWER OF SUPPLIERS 63
5.3.4 BARGAINING POWER OF BUYERS 63
5.3.5 INTENSITY OF COMPETITIVE RIVALRY 63
5.4 REGULATORY TRENDS 63
5.4.1 REGULATORY TRENDS FOR MULTIMODAL IMAGING MARKET 63
5.5 REGULATORY ANALYSIS 64
5.5.1 NORTH AMERICA 64
5.5.1.1 US 64
TABLE 5 US FDA: MEDICAL DEVICE CLASSIFICATION 64
TABLE 6 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 65
5.5.1.2 Canada 65
TABLE 7 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 65
5.5.2 EUROPE 66
5.5.3 ASIA PACIFIC 66
5.5.3.1 Japan 66
TABLE 8 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA 67
5.5.3.2 China 67
TABLE 9 CHINA: CLASSIFICATION OF MEDICAL DEVICES 67
5.5.3.3 India 68
5.6 REIMBURSEMENT SCENARIO 69
TABLE 10 MEDICAL REIMBURSEMENT CPT CODES FOR MULTIMODAL IMAGING PROCEDURES IN US (AS OF 2021) 69
5.7 ECOSYSTEM MAPPING 70
5.8 VALUE CHAIN ANALYSIS 70
5.8.1 RESEARCH & PRODUCT DEVELOPMENT 70
5.8.2 RAW MATERIAL AND MANUFACTURING 71
5.8.3 MARKETING & SALES, SHIPMENT, AND POST-SALES SERVICES 71
FIGURE 19 VALUE CHAIN ANALYSIS—MAXIMUM VALUE ADDED DURING MANUFACTURING PHASE 71
5.9 SUPPLY CHAIN ANALYSIS 72
5.9.1 PROMINENT COMPANIES 72
5.9.2 SMALL AND MEDIUM-SIZED ENTERPRISES 72
5.9.3 END USERS 72
TABLE 11 MULTIMODAL IMAGING MARKET: SUPPLY CHAIN ECOSYSTEM 72
FIGURE 20 MULTIMODAL IMAGING MARKET: SUPPLY CHAIN ANALYSIS 73
5.10 PATENT ANALYSIS 74
FIGURE 21 PATENTS FOR PET/CT IMAGING SYSTEMS (JANUARY 2013–JULY 2023) 74
FIGURE 22 PATENTS FOR PET/MR IMAGING SYSTEMS (JANUARY 2013–JULY 2023) 75
FIGURE 23 PATENTS FOR SPECT/CT IMAGING SYSTEMS (JANUARY 2013–JULY 2023) 76
FIGURE 24 PATENTS FOR OCT IMAGING SYSTEMS (JANUARY 2013–JULY 2023) 77
5.11 TRADE ANALYSIS 78
5.11.1 MULTIMODAL IMAGING MARKET: TRADE ANALYSIS 78
TABLE 12 IMPORT DATA FOR MULTIMODAL IMAGING (HS CODE 901820), BY COUNTRY, 2018–2022 (USD) 78
TABLE 13 EXPORT DATA FOR MULTIMODAL IMAGING (HS CODE 901820), BY COUNTRY, 2018–2022 (USD) 78
5.12 KEY CONFERENCES AND EVENTS 79
TABLE 14 MULTIMODAL IMAGING MARKET: LIST OF KEY CONFERENCES AND EVENTS (2023–2025) 79
5.13 TECHNOLOGY ANALYSIS 80
5.14 CASE STUDY ANALYSIS 81
TABLE 15 CASE STUDY 1: MAINTAINING STRONG FOCUS ON TECHNOLOGICAL INNOVATION AND ADDRESSING REGULATORY COMPLIANCE 81
TABLE 16 CASE STUDY 2: PROVIDING COMPREHENSIVE TRAINING PROGRAMS FOR EVOLVING MULTIMODAL IMAGING TECHNIQUES 82
5.15 PRICING ANALYSIS 82
TABLE 17 REGION-WISE PRICE RANGE FOR MULTIMODAL IMAGING SYSTEMS 82
6 MULTIMODAL IMAGING MARKET, BY TECHNOLOGY 83
6.1 INTRODUCTION 84
TABLE 18 MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 84
6.2 PET/CT SYSTEMS 84
6.2.1 TECHNOLOGICAL ADVANCEMENTS TO SUPPORT MARKET GROWTH 84
TABLE 19 PET/CT MULTIMODAL IMAGING SYSTEMS MARKET, BY REGION, 2021–2028 (USD MILLION) 85
TABLE 20 PET/CT MULTIMODAL IMAGING SYSTEMS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 86
TABLE 21 PET/CT MULTIMODAL IMAGING SYSTEMS MARKET, BY END USER, 2021–2028 (USD MILLION) 86
6.3 SPECT/CT SYSTEMS 87
6.3.1 INCREASING APPLICATIONS OF SPECT/CT SYSTEMS TO DRIVE MARKET 87
TABLE 22 SPECT/CT MULTIMODAL IMAGING SYSTEMS MARKET, BY REGION, 2021–2028 (USD MILLION) 88
TABLE 23 SPECT/CT MULTIMODAL IMAGING SYSTEMS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 88
TABLE 24 SPECT/CT MULTIMODAL IMAGING SYSTEMS MARKET, BY END USER, 2021–2028 (USD MILLION) 89
6.4 PET/MR SYSTEMS 89
6.4.1 ADVANTAGES OFFERED OVER PET/CT SYSTEMS FOR DIAGNOSTIC PURPOSES TO PROPEL MARKET 89
TABLE 25 PET/MR MULTIMODAL IMAGING SYSTEMS MARKET, BY REGION, 2021–2028 (USD MILLION) 90
TABLE 26 PET/MR MULTIMODAL IMAGING SYSTEMS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 91
TABLE 27 PET/MR MULTIMODAL IMAGING SYSTEMS MARKET, BY END USER, 2021–2028 (USD MILLION) 91
6.5 OCT/FMT SYSTEMS 92
6.5.1 INCREASING APPLICATIONS IN RETINAL DISEASE DIAGNOSIS TO DRIVE MARKET 92
TABLE 28 OCT/FMT MULTIMODAL IMAGING SYSTEMS MARKET, BY REGION, 2021–2028 (USD MILLION) 92
TABLE 29 OCT/FMT MULTIMODAL IMAGING SYSTEMS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 93
TABLE 30 OCT/FMT MULTIMODAL IMAGING SYSTEMS MARKET, BY END USER, 2021–2028 (USD MILLION) 93
6.6 OTHER MULTIMODAL IMAGING SYSTEMS 94
TABLE 31 OTHER MULTIMODAL IMAGING SYSTEMS MARKET, BY REGION, 2021–2028 (USD MILLION) 94
TABLE 32 OTHER MULTIMODAL IMAGING SYSTEMS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 95
TABLE 33 OTHER MULTIMODAL IMAGING SYSTEMS MARKET, BY END USER, 2021–2028 (USD MILLION) 95
7 MULTIMODAL IMAGING MARKET, BY APPLICATION 96
7.1 INTRODUCTION 97
TABLE 34 MULTIMODAL IMAGING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 97
7.2 ONCOLOGY 97
7.2.1 INCREASING DEMAND FOR EARLY AND ACCURATE CANCER DIAGNOSIS TO DRIVE MARKET 97
TABLE 35 MULTIMODAL IMAGING MARKET FOR ONCOLOGY APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 98
7.3 CARDIOLOGY 98
7.3.1 RISING PREVALENCE OF CARDIAC DISORDERS TO DRIVE GROWTH 98
TABLE 36 MULTIMODAL IMAGING MARKET FOR CARDIOLOGY APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 99
7.4 OPHTHALMOLOGY 100
7.4.1 TECHNOLOGICAL INNOVATIONS IN OPHTHALMIC MULTIMODAL IMAGING SYSTEMS TO SUPPORT MARKET GROWTH 100
TABLE 37 MULTIMODAL IMAGING MARKET FOR OPHTHALMOLOGY APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 101
7.5 BRAIN & NEUROLOGY 101
7.5.1 INCREASING INCIDENCE OF BRAIN & NEUROLOGICAL DISORDERS TO PROPEL ADOPTION OF MULTIMODAL IMAGING SYSTEMS 101
TABLE 38 MULTIMODAL IMAGING MARKET FOR BRAIN & NEUROLOGY APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 102
7.6 RESEARCH 102
7.6.1 CAPABILITY TO PROVIDE COMPREHENSIVE AND SYNERGISTIC INSIGHTS INTO COMPLEX PHENOMENA TO SUPPORT MARKET GROWTH 102
TABLE 39 MULTIMODAL IMAGING MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 103
7.7 OTHER APPLICATIONS 103
TABLE 40 MULTIMODAL IMAGING MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 104
8 MULTIMODAL IMAGING MARKET, BY END USER 105
8.1 INTRODUCTION 106
TABLE 41 MULTIMODAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 106
8.2 HOSPITALS 106
8.2.1 HIGH PROCEDURAL VOLUMES TO ENSURE SUSTAINED DEMAND FOR MULTIMODAL IMAGING 106
TABLE 42 MULTIMODAL IMAGING MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION) 107
8.3 DIAGNOSTIC IMAGING CENTERS 107
8.3.1 INCREASING NUMBER OF PRIVATE IMAGING CENTERS TO SUPPORT MARKET GROWTH 107
TABLE 43 MULTIMODAL IMAGING MARKET FOR DIAGNOSTIC IMAGING CENTERS, BY REGION, 2021–2028 (USD MILLION) 108
8.4 ACADEMIC & RESEARCH INSTITUTES 108
8.4.1 GROWING AVAILABILITY OF RESEARCH GRANTS AND FUNDING TO DRIVE MARKET 108
TABLE 44 MULTIMODAL IMAGING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 109
8.5 OTHER END USERS 109
TABLE 45 MULTIMODAL IMAGING MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 110
9 MULTIMODAL IMAGING MARKET, BY REGION 111
9.1 INTRODUCTION 112
TABLE 46 MULTIMODAL IMAGING MARKET, BY REGION, 2021–2028 (USD MILLION) 112
9.2 NORTH AMERICA 112
9.2.1 RECESSION IMPACT 112
FIGURE 25 NORTH AMERICA: MULTIMODAL IMAGING MARKET SNAPSHOT 113
TABLE 47 NORTH AMERICA: MULTIMODAL IMAGING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 48 NORTH AMERICA: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 114
TABLE 49 NORTH AMERICA: MULTIMODAL IMAGING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 115
TABLE 50 NORTH AMERICA: MULTIMODAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 115
9.2.2 US 116
9.2.2.1 Rising geriatric population to drive market 116
TABLE 51 US: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 117
9.2.3 CANADA 117
9.2.3.1 Government investments to support market growth 117
TABLE 52 CANADA: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 118
9.3 EUROPE 118
9.3.1 RECESSION IMPACT 118
TABLE 53 EUROPE: MULTIMODAL IMAGING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 54 EUROPE: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 119
TABLE 55 EUROPE: MULTIMODAL IMAGING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 120
TABLE 56 EUROPE: MULTIMODAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 120
9.3.2 GERMANY 121
9.3.2.1 Increasing prevalence of chronic diseases to drive market 121
TABLE 57 GERMANY: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 121
9.3.3 FRANCE 122
9.3.3.1 Rising number of diagnostic imaging centers to propel market 122
TABLE 58 FRANCE: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 122
9.3.4 UK 123
9.3.4.1 Government initiatives to support market growth 123
TABLE 59 UK: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 123
9.3.5 ITALY 124
9.3.5.1 Availability of reimbursement coverage to support market growth 124
TABLE 60 ITALY: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 124
9.3.6 SPAIN 125
9.3.6.1 Increasing public funding for cell-based research to propel market 125
TABLE 61 SPAIN: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 125
9.3.7 REST OF EUROPE 126
TABLE 62 REST OF EUROPE: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 126
9.4 ASIA PACIFIC 127
9.4.1 RECESSION IMPACT 127
FIGURE 26 ASIA PACIFIC: MULTIMODAL IMAGING MARKET SNAPSHOT 128
TABLE 63 ASIA PACIFIC: MULTIMODAL IMAGING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 64 ASIA PACIFIC: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 129
TABLE 65 ASIA PACIFIC: MULTIMODAL IMAGING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 130
TABLE 66 ASIA PACIFIC: MULTIMODAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 130
9.4.2 CHINA 131
9.4.2.1 Rapidly growing geriatric population to propel market 131
TABLE 67 CHINA: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 131
9.4.3 JAPAN 132
9.4.3.1 High adoption of advanced technologies to support market growth 132
TABLE 68 JAPAN: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 132
9.4.4 INDIA 133
9.4.4.1 Rising prevalence of various chronic diseases to drive market 133
TABLE 69 INDIA: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 133
9.4.5 AUSTRALIA 134
9.4.5.1 Increasing investments in research to provide opportunities for market growth 134
TABLE 70 AUSTRALIA: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 134
9.4.6 SOUTH KOREA 135
9.4.6.1 Presence of well-developed healthcare system to propel market 135
TABLE 71 SOUTH KOREA: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 135
9.4.7 REST OF ASIA PACIFIC 135
TABLE 72 REST OF ASIA PACIFIC: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 136
9.5 LATIN AMERICA 136
9.5.1 RECESSION IMPACT 136
TABLE 73 LATIN AMERICA: MULTIMODAL IMAGING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 137
TABLE 74 LATIN AMERICA: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 137
TABLE 75 LATIN AMERICA: MULTIMODAL IMAGING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 138
TABLE 76 LATIN AMERICA: MULTIMODAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 138
9.5.2 BRAZIL 139
9.5.2.1 Favorable demographic conditions to drive market 139
TABLE 77 BRAZIL: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 139
9.5.3 MEXICO 140
9.5.3.1 Increased medical tourism and better government healthcare initiatives to drive market 140
TABLE 78 MEXICO: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 140
9.5.4 REST OF LATIN AMERICA 141
TABLE 79 REST OF LATIN AMERICA: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 141
9.6 MIDDLE EAST & AFRICA 142
9.6.1 GROWING MEDICAL TOURISM TO DRIVE MARKET 142
9.6.2 RECESSION IMPACT 142
TABLE 80 MIDDLE EAST & AFRICA: MULTIMODAL IMAGING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 143
TABLE 81 MIDDLE EAST & AFRICA: MULTIMODAL IMAGING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 143
TABLE 82 MIDDLE EAST & AFRICA: MULTIMODAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 144
10 COMPETITIVE LANDSCAPE 145
10.1 OVERVIEW 145
10.2 STRATEGIES ADOPTED BY KEY PLAYERS 145
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN MULTIMODAL IMAGING MARKET 145
10.3 REVENUE SHARE ANALYSIS 146
FIGURE 27 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN MULTIMODAL IMAGING MARKET, 2020–2022 146
10.4 MARKET SHARE ANALYSIS 147
FIGURE 28 MARKET SHARE ANALYSIS OF TOP PLAYERS IN MULTIMODAL IMAGING MARKET, 2022 147
TABLE 83 MULTIMODAL IMAGING MARKET: DEGREE OF COMPETITION 147
10.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022) 149
10.5.1 STARS 149
10.5.2 EMERGING LEADERS 149
10.5.3 PERVASIVE PLAYERS 149
10.5.4 PARTICIPANTS 149
FIGURE 29 MULTIMODAL IMAGING MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022 150
10.6 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022) 151
10.6.1 PROGRESSIVE COMPANIES 151
10.6.2 STARTING BLOCKS 151
10.6.3 RESPONSIVE COMPANIES 151
10.6.4 DYNAMIC COMPANIES 151
FIGURE 30 MULTIMODAL IMAGING MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2022 152
10.7 COMPETITIVE BENCHMARKING 153
TABLE 84 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF COMPANIES 153
TABLE 85 PRODUCT FOOTPRINT ANALYSIS OF COMPANIES 154
TABLE 86 REGIONAL FOOTPRINT ANALYSIS OF COMPANIES 155
10.8 COMPETITIVE SCENARIO AND TRENDS 156
TABLE 87 PRODUCT LAUNCHES, JANUARY 2020–JULY 2023 156
TABLE 88 DEALS, JANUARY 2020–JULY 2023 157
TABLE 89 OTHER DEVELOPMENTS, JANUARY 2020–JULY 2023 158
11 COMPANY PROFILES 160
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *
11.1 KEY PLAYERS 160
11.1.1 GE HEALTHCARE 160
TABLE 90 GE HEALTHCARE: COMPANY OVERVIEW 160
FIGURE 31 GE HEALTHCARE: COMPANY SNAPSHOT (2022) 161
11.1.2 KONINKLIJKE PHILIPS N.V. 166
TABLE 91 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW 166
FIGURE 32 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2022) 167
11.1.3 CANON MEDICAL SYSTEMS CORPORATION 170
TABLE 92 CANON MEDICAL SYSTEMS CORPORATION: COMPANY OVERVIEW 170
FIGURE 33 CANON MEDICAL SYSTEMS CORPORATION: COMPANY SNAPSHOT (2022) 171
11.1.4 SIEMENS HEALTHINEERS 174
TABLE 93 SIEMENS HEALTHINEERS: COMPANY OVERVIEW 174
FIGURE 34 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2022) 175
11.1.5 ZEISS GROUP 178
TABLE 94 ZEISS GROUP: COMPANY OVERVIEW 178
FIGURE 35 CARL ZEISS MEDITEC GROUP: COMPANY SNAPSHOT (2022) 179
11.1.6 BRUKER 182
TABLE 95 BRUKER: COMPANY OVERVIEW 182
FIGURE 36 BRUKER: COMPANY SNAPSHOT (2022) 183
11.1.7 MEDISO LTD. 185
TABLE 96 MEDISO LTD.: COMPANY OVERVIEW 185
11.1.8 NEUSOFT CORPORATION. 187
TABLE 97 NEUSOFT CORPORATION: COMPANY OVERVIEW 187
11.1.9 INFRAREDX, INC. (PART OF NIPRO CORPORATION) 190
TABLE 98 INFRAREDX, INC.: COMPANY OVERVIEW 190
FIGURE 38 NIPRO CORPORATION: COMPANY SNAPSHOT (2022) 191
11.1.10 TOPCON CORPORATION 192
TABLE 99 TOPCON CORPORATION: COMPANY OVERVIEW 192
FIGURE 39 TOPCON CORPORATION: COMPANY SNAPSHOT (2022) 193
11.1.11 SHANGHAI UNITED IMAGING HEALTHCARE CO., LTD. 195
TABLE 100 SHANGHAI UNITED IMAGING HEALTHCARE CO., LTD.: COMPANY OVERVIEW 195
11.1.12 HEIDELBERG ENGINEERING 198
TABLE 101 HEIDELBERG ENGINEERING: COMPANY OVERVIEW 198
11.1.13 SPECTRUM DYNAMICS MEDICAL 200
TABLE 102 SPECTRUM DYNAMICS MEDICAL: COMPANY OVERVIEW 200
11.1.14 MINFOUND MEDICAL SYSTEMS CO., LTD. 202
TABLE 103 MINFOUND MEDICAL SYSTEMS CO., LTD.: COMPANY OVERVIEW 202
11.1.15 KINDSWAY BIOTECH 204
TABLE 104 KINDSWAY BIOTECH: COMPANY OVERVIEW 204
11.2 OTHER COMPANIES 205
11.2.1 SOFIE BIOSCIENCES, INC. 205
11.2.2 REFLEXION MEDICAL, INC. 205
11.2.3 CUBRESA INC. 206
11.2.4 FUJIFILM CORPORATION 206
11.2.5 POSITRON 207
11.2.6 MR SOLUTIONS 208
11.2.7 ALCON INC. 209
11.2.8 ESSILOR INSTRUMENTS USA 209
11.2.9 NIDEK CO., LTD. 210
11.2.10 ZIEMER OPHTHALMIC SYSTEMS AG 210
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
12 APPENDIX 211
12.1 DISCUSSION GUIDE 211
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 214
12.3 CUSTOMIZATION OPTIONS 216
12.4 RELATED REPORTS 216
12.5 AUTHOR DETAILS 217

ページTOPに戻る

Table of Contents

Summary

The global multimodal market is projected to reach USD 5.5 billion by 2028 from USD 4.2 billion in 2023, at a CAGR of 5.7% from 2023 to 2028. Factors such as the high incidence/prevalence of target diseases, the growing number of diagnostic imaging centers/procedures, increasing awareness about the benefits of early diagnosis of diseases, and the rapid adoption of technologically advanced imaging systems, features and modalities are responsible for the increasing growth of this market.

“The PET-CT segment of technology segment l held the largest share of the market in 2022”
Based on technology, the multimodal market is segmented into PET-CT, PET/MR, SPECT-CT, OCT/FMT and other multimodal imaging . The PET-CT segment held a major share of the market. Conducting PET and CT scans in a single session reduces radiation exposure and scan time, while its clinical versatility spans oncology, cardiology, neurology, and infectious diseases. Despite initial costs, the cost-effectiveness of PET-CT emerges from improved diagnostics, reduced need for additional tests, and research advancements, making it a valuable tool that significantly benefits patient outcomes and medical research are driving the growth of this product segment.

“The oncology segment is projected to register the highest CAGR during the forecast period”
Based on application, the multimodal market is segmented into brain & neurology, cardiology, oncology, ophthalmology, research and other applications. The oncology segment accounted for the largest market share in 2022. The large share of this segment is attributed to the system’s versatility, image quality, ehanced, easy to use features, and due to the increased usage of it in acute care settings and emergency care in hospitals and healthcare institutions.

“The diagnostic imaging centers segment for end user segment is projected to register a significant CAGR during the forecast period”
On the basis of end user, the multimodal market is segmented into hospitals, diagnostic imaging cneters, academic and research institutes. The diagnostic imaging centers segment accounted for the largest share of the multimodal market in 2022. By integrating multiple imaging modalities, such as PET-CT, MRI-PET, or SPECT-CT, diagnostic imaging centers can provide more accurate and reliable diagnoses, leading to better treatment planning and improved patient outcomes. Moreover, the versatility of multimodal imaging enables these centers to cater to a wide range of medical specialties, effectively serving patients with diverse healthcare needs.

“The market in the North America region is expected to witness the highest growth during the forecast period.”
The multimodal market in the North America region is expected to register a CAGR during the forecast period, primarily due to the high healthcare spending in the region, rising prevalence of target diseases, increasing research activities, growing number of cosmetic surgeries, and technological advancements in imaging systems.

A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1–48%, Tier 2–36%, and Tier 3– 16%
• By Designation: Director-level–14%, C-level–10%, and Others–76%
• By Region: North America–40%, Europe–32%, Asia Pacific–20%, Latin America–5%, and the Middle East & Africa–3%

The prominent players in the multimodal market are GE Healthcare (US), Koninklijke Philips N.V. (Netherlands), Canon Medical Systems Corporation (Japan), Siemens AG (Germany), Neusoft (China), Topcon Corporation (Japan), and Bruker (US) among others.

Research Coverage

This report studies the multimodal market based on technology, display, portability, component, application, enduser, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).

Reasons to Buy the Report
The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall multimodal market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.

This report provides insights on the following pointers:
• Analysis of key drivers (rising target patient population, growing adoption of multimodal imaging devices, technological advancement, and increasing investment, funds, and grants by public-private organizations), restraints (high capital and operational cost, unfavorable regulatory guidelines), opportunities (improving healthcare infrastructure across emerging countries, PET utilization for breast imaging, promising product pipeline), and challenges (availability of alternate imaging technologies) influencing the growth of the multimodal market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the multimodal market
• Market Development: Comprehensive information about lucrative markets–the report analyses the multimodal market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the multimodal market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like GE Healthcare (US), Koninklijke Philips N.V. (Netherlands), Canon Medical Systems Corporation (Japan), Siemens AG (Germany), Neusoft (China), Topcon Corporation (Japan), and Bruker (US) among others.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医療機器）の最新刊レポート

MarketsandMarkets社のMedical Devices分野での最新刊レポート

本レポートと同じKEY WORD（oncology）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

マルチモーダルイメージング市場：技術別（PET-CT、SPECT-CT、PET-MR、OCT/FMT）、用途別（腫瘍学、心臓病学、脳科学、眼科学）、エンドユーザー別（病院、診断センター、学術機関、研究）、地域別 - 2028年までの世界予測

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（医療機器）の最新刊レポート

MarketsandMarkets社のMedical Devices分野での最新刊レポート

本レポートと同じKEY WORD（oncology）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?